Clinical Trial Update: Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of daratumumab, thalidomide, and dexamethasone in relapsed and/or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• Thalomid (thalidomide)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Relapse and / or Refractory Myeloma | Phase 2 | Status: UNKNOWN